Relay Therapeutics beat analyst estimates for both GAAP revenue and earnings per share in Q2 2025. The company reported continued clinical advancement of its lead asset RLY-2608, with new positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback